nab-sirolimus
Showing 1 - 25 of 1,293
Endometrial Cancer, Endometrioid Tumor, Cancer Trial in Oklahoma City (nab-sirolimus)
Not yet recruiting
- Endometrial Cancer
- +5 more
- nab-sirolimus
-
Oklahoma City, OklahomaUniversity Oklahoma Stephenson Cancer Center
Aug 16, 2023
Solid Tumor, Adult, NSCLC, Advanced Cancer Trial (Adagrasib, nab-Sirolimus)
Not yet recruiting
- Solid Tumor, Adult
- +4 more
- Adagrasib
- nab-Sirolimus
- (no location specified)
Apr 24, 2023
Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor Trial in Newport Beach, Denver, Dallas (nab-sirolimus)
Not yet recruiting
- Neuroendocrine Tumors
- +4 more
- nab-sirolimus
-
Newport Beach, California
- +2 more
Aug 16, 2023
Tumor, Solid, Tumor, Advanced Solid Tumor Trial in San Antonio, West Valley City (nab-sirolimus)
Recruiting
- Tumor, Solid
- +2 more
- nab-sirolimus
-
San Antonio, Texas
- +1 more
Dec 14, 2022
Childhood Solid Tumor, Recurrent Malignant Solid Tumor, Recurrent Primary CNS Tumor Trial in United States (Irinotecan
Active, not recruiting
- Childhood Solid Neoplasm
- +4 more
- Irinotecan Hydrochloride
- +4 more
-
Birmingham, Alabama
- +20 more
Feb 1, 2023
Tumor, Tumor, Solid, Metastasis Trial in United States (nab-sirolimus)
Recruiting
- Tumor
- +20 more
- nab-sirolimus
-
Mobile, Alabama
- +81 more
Jan 24, 2023
Non-muscle Invasive Bladder Cancer (NMIBC) Trial in New York, Nashville (ABI-009, Gemcitabine)
Completed
- Non-muscle Invasive Bladder Cancer (NMIBC)
-
New York, New York
- +1 more
May 12, 2021
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma Trial in Fullerton, Newport Beach, Santa Monica (ABI-009,
Active, not recruiting
- High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
- ABI-009
- +5 more
-
Fullerton, California
- +2 more
Jun 13, 2022
Methylmalonic Acidemia (MMA) Trial run by the Selecta Biosciences, Inc. (SEL-302)
Recruiting
- Methylmalonic Acidemia (MMA)
-
Bethesda, MarylandNational Human Genome Research Institute, National Institutes of
Mar 9, 2023
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma Trial in United States (Gemcitabine combined with
Recruiting
- Metastatic Pancreatic Cancer
- Metastatic Pancreatic Adenocarcinoma
- Gemcitabine combined with nab-paclitaxel
- +4 more
-
La Jolla, California
- +20 more
Aug 18, 2022
Pulmonary Hypertension Trial in United States (ABI-009, nab-rapamycin, albumin-bound rapamycin)
Active, not recruiting
- Pulmonary Hypertension
- ABI-009, nab-rapamycin, albumin-bound rapamycin
-
Tucson, Arizona
- +5 more
Aug 22, 2022
Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma Trial in Seattle
Recruiting
- Advanced Soft Tissue Sarcoma
- +2 more
- Nanoparticle Albumin-Bound Rapamycin
- Pazopanib hydrochloride
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 16, 2022
Triple-negative Breast Cancer Trial in Shanghai (Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or
Recruiting
- Triple-negative Breast Cancer
- Pyrotinib with Capecitabine
- +6 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 8, 2022
Bronchiolitis Obliterans Syndrome Due to and After Lung Transplantation (Disorder), Chronic Lung Allograft Dysfunction Trial in
Recruiting
- Bronchiolitis Obliterans Syndrome Due to and After Lung Transplantation (Disorder)
- Chronic Lung Allograft Dysfunction
- Sirolimus
- Placebo
-
San Francisco, CaliforniaUniversity of California, San Francisco
Aug 28, 2023
Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma Trial in
Not yet recruiting
- Pancreas Adenocarcinoma
- +2 more
- Nab paclitaxel
- +3 more
-
Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
Apr 19, 2023
Pancreatic Cancer Trial (TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine,
Not yet recruiting
- Pancreatic Cancer
- TTX-030, nab-paclitaxel and gemcitabine
- +2 more
- (no location specified)
Nov 3, 2023
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma Trial (Nab paclitaxel,
Not yet recruiting
- Pancreatic Acinar Cell Carcinoma
- +6 more
- Nab paclitaxel
- +5 more
- (no location specified)
Oct 30, 2023
Metastatic Pancreatic Ductal Adenocarcinoma Trial in Worldwide (NIS793, Nab-paclitaxel, Gemcitabine)
Recruiting
- Metastatic Pancreatic Ductal Adenocarcinoma
- NIS793
- +3 more
-
Fayetteville, Arkansas
- +122 more
Jan 27, 2023
Triple-Negative Breast Cancer Trial in Shanghai (VEGFR, nab-paclitaxel, Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin)
Recruiting
- Triple-Negative Breast Cancer
- VEGFR
- +2 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Mar 28, 2023
Bladder Cancer Trial in Tianjin (Cadonilimab)
Recruiting
- Bladder Cancer
-
Tianjin, Tianjin, ChinaTianjin Medical University Second Hospital
Aug 23, 2023
Triple-Negative Breast Cancer Trial in Shanghai (Camrelizumab plus Famitinib with/without nab-Palitaxel)
Not yet recruiting
- Triple-Negative Breast Cancer
- Camrelizumab plus Famitinib with/without nab-Palitaxel
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center Shanghai, China, 200032
Jan 2, 2023
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,
Recruiting
- Cervical Adenocarcinoma
- +47 more
- Bevacizumab
- +3 more
-
Phoenix, Arizona
- +3 more
Dec 5, 2022